About Zimmer Biomet (NYSE:ZBH)
Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
Industry, Sector and Symbol
Industry Medical Equipment, Supplies & Distribution
Trailing P/E Ratio38.0373831775701
Forward P/E Ratio15.21
Sales & Book Value
Annual Sales$7.68 billion
Price / Sales3.22
Cash Flow$13.37 per share
Price / Cash9.13
Book Value$48.28 per share
Price / Book2.53
Net Income$305.90 million
Return on Equity16.29%
Return on Assets6.17%
Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions
What is Zimmer Biomet's stock symbol?
Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."
How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?
Zimmer Biomet declared a quarterly dividend on Monday, December 18th. Stockholders of record on Friday, December 29th will be paid a dividend of $0.24 per share on Monday, January 29th. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. The ex-dividend date is Thursday, December 28th. View Zimmer Biomet's Dividend History.
How were Zimmer Biomet's earnings last quarter?
Zimmer Biomet Holdings Inc (NYSE:ZBH) announced its quarterly earnings results on Wednesday, November, 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts' consensus estimates of $1.74 by $0.02. The medical equipment provider had revenue of $1.82 billion for the quarter, compared to analysts' expectations of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The company's revenue was down .8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.79 earnings per share. View Zimmer Biomet's Earnings History.
When will Zimmer Biomet make its next earnings announcement?
What guidance has Zimmer Biomet issued on next quarter's earnings?
Zimmer Biomet issued an update on its FY17 earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of $8.01-$8.07 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.23. The company issued revenue guidance of $7.76-$7.80 billion, compared to the consensus revenue estimate of $7.83 billion.Zimmer Biomet also updated its Q4 guidance to $2.08-$2.14 EPS.
Where is Zimmer Biomet's stock going? Where will Zimmer Biomet's stock price be in 2018?
21 brokers have issued 12 month price objectives for Zimmer Biomet's shares. Their predictions range from $120.00 to $158.00. On average, they anticipate Zimmer Biomet's share price to reach $137.42 in the next twelve months. View Analyst Ratings for Zimmer Biomet.
What are Wall Street analysts saying about Zimmer Biomet stock?
Here are some recent quotes from research analysts about Zimmer Biomet stock:
- 1. Canaccord Genuity analysts commented, "We maintain our HOLD rating following the announcement that Zimmer has named Bryan Hanson, former EVP and President of Medtronic’s Minimally Invasive Therapies Group, as CEO effective immediately. The announcement ends the five-month search for a new leader after former CEO David Dvorak resigned early in the Q3/17. Additionally, interim CEO Dan Florin will remain with the company as CFO. We view the hire positively as it removes the near-term overhang of management uncertainty and adds a seasoned medtech veteran to the management team and board. Additionally, we expect the new CEO to be well received by investors given our recent diligence suggested Mr. Hanson was at the top of investors’ short list of potential candidates." (12/19/2017)
- 2. According to Zacks Investment Research, "Zimmer Biomet ended the third quarter 2017 on a dismal note with earnings below the Zacks Consensus Estimate and revenues in line with the same. Sales were declining within most of the core segments primarily due to the slower pace of supply recovery and sales recapture of certain key brands particularly in the United States and softened domestic market conditions. The lowered 2017 guidance also added to our concerns indicating little chances of recovery ahead. Over, the last three months, the company has been observed to trade below the broader industry. Nevertheless, we look forward to the expected synergy from the LDR Holding acquisition, which should broaden and complement the company's musculoskeletal offering. We are also impressed by the strong strategic and financial goals which the combined entity expects to reach, now that the deal has been closed." (11/20/2017)
- 3. Needham & Company LLC analysts commented, "We hosted a dinner and investor meetings with Dan Florin, Senior Vice President and CFO, and Bob Marshall, Treasurer and Vice President of Investor Relations this week in New York City. We think that the discussion was upbeat and highlighted ZBH's progress in addressing its manufacturing challenges, its non-recon business performance, margin opportunities, and cash flow outlook. The meetings reinforced our view that ZBH should be able to drive its revenue growth to sustainable mid-single digit growth with a combination of market growth in recon and above-market growth in its non-recon businesses. We reiterate our Strong Buy rating." (2/17/2017)
Who are some of Zimmer Biomet's key competitors?
Some companies that are related to Zimmer Biomet include Covidien (COV), Baxter International (BAX), C R Bard (BCR), Align Technology (ALGN), DENTSPLY SIRONA (XRAY), CareFusion (CFN), Bio-Rad Laboratories (BIO), Steris (STE), West Pharmaceutical Services (WST), Hill-Rom (HRC), DexCom (DXCM), ICU Medical (ICUI), VWR (VWR), Globus Medical (GMED), Integra Lifesciences (IART), LivaNova (LIVN), Haemonetics (HAE) and NuVasive (NUVA).
Who are Zimmer Biomet's key executives?
Zimmer Biomet's management team includes the folowing people:
- Bryan C. Hanson, President, Chief Executive Officer, Director (Age 50)
- Daniel P. Florin, Chief Financial Officer, Senior Vice President (Age 53)
- Robert D. Delps, President, Americas
- Katarzyna Mazur-Hofsaess M.D. Ph.D., President, Europe, Middle East and Africa (Age 52)
- Sang Yi, President, Asia Pacific (Age 54)
- Chad F. Phipps, Senior Vice President, General Counsel, Secretary (Age 44)
- Larry C. Glasscock, Independent Non-Executive Chairman of the Board (Age 69)
- Christopher B. Begley, Independent Director (Age 65)
- Betsy J. Bernard, Independent Director (Age 61)
- Gail Koziara Boudreaux, Independent Director (Age 56)
Who owns Zimmer Biomet stock?
Zimmer Biomet's stock is owned by many different of retail and institutional investors. Top institutional investors include Hexavest Inc. (0.16%), Stock Yards Bank & Trust Co. (0.03%), Exxonmobil Investment Management Inc. TX (0.02%), QUANTRES ASSET MANAGEMENT Ltd (0.01%), Daiwa SB Investments Ltd. (0.00%) and Boltwood Capital Management (0.00%). Company insiders that own Zimmer Biomet stock include Blackstone Capital Partners V, Chad F Phipps, Daniel E Williamson, Daniel P Florin, David A Jr Nolan, David C Dvorak, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.
Who sold Zimmer Biomet stock? Who is selling Zimmer Biomet stock?
Zimmer Biomet's stock was sold by a variety of institutional investors in the last quarter, including Exxonmobil Investment Management Inc. TX, Stock Yards Bank & Trust Co. and Boyd Watterson Asset Management LLC OH. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, David C Dvorak, Sang Yi and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet.
Who bought Zimmer Biomet stock? Who is buying Zimmer Biomet stock?
Zimmer Biomet's stock was purchased by a variety of institutional investors in the last quarter, including QUANTRES ASSET MANAGEMENT Ltd, Hexavest Inc., Boltwood Capital Management, Chesley Taft & Associates LLC and Daiwa SB Investments Ltd.. View Insider Buying and Selling for Zimmer Biomet.
How do I buy Zimmer Biomet stock?
Shares of Zimmer Biomet can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zimmer Biomet's stock price today?
One share of Zimmer Biomet stock can currently be purchased for approximately $122.10.
How big of a company is Zimmer Biomet?
Zimmer Biomet has a market capitalization of $24.72 billion and generates $7.68 billion in revenue each year. The medical equipment provider earns $305.90 million in net income (profit) each year or $3.21 on an earnings per share basis. Zimmer Biomet employs 18,500 workers across the globe.
How can I contact Zimmer Biomet?
Zimmer Biomet's mailing address is 345 E Main St, WARSAW, IN 46580-2746, United States. The medical equipment provider can be reached via phone at +1-574-2676131 or via email at [email protected]
MarketBeat Community Rating for Zimmer Biomet (ZBH)MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Zimmer Biomet (NYSE:ZBH) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.81||2.68||2.67||2.74|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
|1 Sell Rating(s)|
6 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
|1 Sell Rating(s)|
6 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
|1 Sell Rating(s)|
5 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$137.42||$135.75||$138.47||$139.57|
|Price Target Upside: ||10.17% upside||19.56% upside||18.26% upside||5.25% upside|
Zimmer Biomet (NYSE:ZBH) Consensus Price Target History
Zimmer Biomet (NYSE:ZBH) Analyst Ratings History
(Data available from 1/16/2016 forward)
Zimmer Biomet (NYSE:ZBH) Earnings History and Estimates Chart
Zimmer Biomet (NYSE ZBH) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/1/2017||Q3 2017||$1.74||$1.72||$1.83 billion||$1.82 billion||View||N/A|
|7/27/2017||Q2 2017||$2.10||$2.08||$1.95 billion||$1.95 billion||View||N/A|
|4/27/2017||Q1 2017||$2.11||$2.13||$1.96 billion||$1.98 billion||View||N/A|
|1/31/2017||Q416||$2.11||$2.14||$1.98 billion||$2.01 billion||View||Listen|
|10/31/2016||Q316||$1.79||$1.79||$950.20 million||$1.83 billion||View||Listen|
|7/28/2016||Q216||$1.97||$2.02||$1.90 billion||$1.93 billion||View||Listen|
|4/28/2016||Q116||$1.93||$2.00||$1.88 billion||$1.90 billion||View||Listen|
|1/28/2016||Q415||$2.04||$2.09||$1.96 billion||$1.98 billion||View||Listen|
|10/29/2015||Q315||$1.56||$1.64||$1.76 billion||$1.76 billion||View||Listen|
|4/30/2015||Q115||$1.54||$1.58||$1.15 billion||$1.13 billion||View||N/A|
|1/29/2015||Q414||$1.71||$0.91||$1.25 billion||$1.22 billion||View||N/A|
|10/23/2014||Q314||$1.00||$0.96||$1.10 billion||$1.11 billion||View||Listen|
|7/24/2014||Q214||$1.49||$1.49||$1.21 billion||$1.18 billion||View||N/A|
|4/24/2014||Q114||$1.47||$1.50||$1.18 billion||$1.16 billion||View||Listen|
|1/31/2014||Q114||$1.62||$1.36||$1.22 billion||$1.24 billion||View||N/A|
|10/24/2013||Q313||$1.24||$1.25||$1.06 billion||$1.07 billion||View||N/A|
|7/25/2013||Q2 2013||$1.44||$1.43||$1.15 billion||$1.17 billion||View||N/A|
|4/25/2013||Q1 2013||$1.40||$1.41||$1.14 billion||$1.14 billion||View||N/A|
|1/31/2013||Q4 2012||$1.49||$1.51||$1.17 billion||$1.18 billion||View||N/A|
Zimmer Biomet (NYSE:ZBH) Earnings Estimates
2018 EPS Consensus Estimate: $8.14
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Zimmer Biomet (NYSE:ZBH) Dividend Information
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||29.91% (Trailing 12 Months of Earnings) |
11.96% (Based on This Year's Estimates)
11.74% (Based on Next Year's Estimates)
|Track Record:||2 Years of Consecutive Dividend Growth|
Zimmer Biomet (NYSE:ZBH) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Zimmer Biomet (NYSE ZBH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.07%
Institutional Ownership Percentage: 86.06%
Zimmer Biomet (NYSE ZBH) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/31/2017||Tony W. Collins||VP||Sell||16,986||$121.74||$2,067,875.64|| |
|6/12/2017||Sang Yi||Insider||Sell||17,731||$124.56||$2,208,573.36|| |
|5/5/2017||Chad F. Phipps||VP||Sell||6,200||$116.76||$723,912.00|| |
|4/27/2017||David C Dvorak||Insider||Sell||87,331||$116.47||$10,171,441.57||381,886|| |
|3/20/2017||David C Dvorak||Insider||Sell||1,040||$121.63||$126,495.20||294,077|| |
|12/2/2016||David A. Jr. Nolan||Insider||Sell||5,050||$101.11||$510,605.50|| |
|9/8/2016||Daniel E Williamson||Insider||Sell||2,716||$129.96||$352,971.36||2,000|| |
|8/23/2016||Stuart G Kleopfer||Insider||Sell||3,397||$129.71||$440,624.87||3,000|| |
|8/12/2016||Tony W. Collins||VP||Sell||1,287||$129.16||$166,228.92|| |
|8/9/2016||Stuart G Kleopfer||Insider||Sell||533||$132.71||$70,734.43||6,397|| |
|8/1/2016||David A. Jr. Nolan||Insider||Sell||25,255||$130.77||$3,302,596.35|| |
|7/11/2016||Daniel P Florin||CFO||Sell||15,000||$124.98||$1,874,700.00||16,983|| |
|6/14/2016||Tony W Collins||CAO||Sell||3,611||$116.43||$420,428.73||3,245|| |
|6/9/2016||Stuart G Kleopfer||Insider||Sell||11,000||$119.45||$1,313,950.00||7,609|| |
|4/14/2016||Daniel P Florin||CFO||Sell||10,000||$114.98||$1,149,800.00||28,415|| |
|4/12/2016||Daniel P Florin||CFO||Sell||12,000||$110.00||$1,320,000.00||38,415|| |
|3/21/2016||David C Dvorak||CEO||Sell||1,540||$104.16||$160,406.40||277,416|| |
|2/10/2016||Blackstone Capital Partners V||Major Shareholder||Sell||7,351,708||$95.91||$705,102,314.28|| |
|1/8/2016||David C. Dvorak||CEO||Sell||44,661||$102.46||$4,575,966.06||244,502|| |
|12/2/2015||David A. Jr. Nolan||insider||Sell||3,435||$102.62||$352,499.70||12,139|| |
|6/30/2015||Adam Rudolph Johnson||Insider||Sell||30,600||$110.34||$3,376,404.00|| |
|6/29/2015||Daniel E Williamson||Insider||Sell||16,000||$110.98||$1,775,680.00|| |
|6/29/2015||Daniel P Florin||CFO||Sell||5,000||$107.00||$535,000.00|| |
|3/17/2015||David C Dvorak||CEO||Sell||1,300||$115.55||$150,215.00|| |
|12/5/2014||David C Dvorak||CEO||Sell||48,703||$115.00||$5,600,845.00|| |
|11/28/2014||Chad F Phipps||VP||Sell||5,000||$112.00||$560,000.00|| |
|11/3/2014||Katarzyna Mazur-Hofsaess||Insider||Sell||28,253||$110.01||$3,108,112.53|| |
|9/9/2014||Stephen Hong Liang Ooi||Insider||Sell||40,768||$102.78||$4,190,135.04|| |
|8/26/2014||James T Crines||CFO||Sell||40,768||$101.00||$4,117,568.00|| |
|1/8/2014||Jeffery Mccaulley||Insider||Sell||21,286||$96.00||$2,043,456.00||5,211|| |
|1/7/2014||Chad Phipps||VP||Sell||7,000||$95.00||$665,000.00||17,240|| |
|12/20/2013||Jeffery Mccaulley||Insider||Sell||21,286||$93.00||$1,979,598.00||5,211|| |
|12/3/2013||Jeffery Mccaulley||Insider||Sell||2,713||$90.12||$244,495.56||5,211|| |
|11/15/2013||Derek Davis||CAO||Sell||3,500||$90.20||$315,700.00||2,791|| |
|11/14/2013||Chad Phipps||VP||Sell||7,800||$90.00||$702,000.00||17,240|| |
|11/14/2013||David Dvorak||CEO||Sell||64,763||$90.00||$5,828,670.00||172,746|| |
|11/14/2013||Jeffery Mccaulley||Insider||Sell||21,285||$90.00||$1,915,650.00||7,924|| |
|9/13/2013||Katarzyna Mazur-Hofsaess||Insider||Sell||4,890||$81.38||$397,948.20||1,643|| |
|8/1/2013||James T Crines||CFO||Sell||46,200||$84.56||$3,906,672.00|| |
|8/1/2013||Stephen Hong Liang Ooi||Insider||Sell||38,500||$84.27||$3,244,395.00|| |
|7/29/2013||Derek M Davis||CAO||Sell||3,725||$83.78||$312,080.50|| |
|7/29/2013||Jeffery A Mccaulley||Insider||Sell||112,255||$83.40||$9,362,067.00|| |
|7/19/2013||Chad F Phipps||VP||Sell||6,000||$83.00||$498,000.00|| |
|5/8/2013||Chad F Phipps||VP||Sell||5,000||$77.26||$386,300.00|| |
|4/30/2013||James T Crines||CFO||Sell||25,000||$76.08||$1,902,000.00|| |
|4/30/2013||Jeffery A Mccaulley||Insider||Sell||10,000||$76.08||$760,800.00|| |
|2/4/2013||Derek M Davis||CAO||Sell||21,864||$72.53||$1,585,795.92|| |
|2/4/2013||Jeffery A Mccaulley||Insider||Sell||12,000||$73.60||$883,200.00|| |
Zimmer Biomet (NYSE ZBH) News Headlines
Zimmer Biomet (NYSE:ZBH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Zimmer Biomet (NYSE:ZBH) Income Statement, Balance Sheet and Cash Flow Statement
Zimmer Biomet (NYSE ZBH) Stock Chart for Tuesday, January, 16, 2018